Sinovac Biotech Ltd. is a holding company that conducts its business in China, through its 71.56%-owned subsidiary, Sinovac Beijing, and its wholly owned subsidiaries, Tangshan Yian and Sinovac Hong Kong. It is an integrated biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. The Company’s portfolio of products consists of vaccines against the hepatitis A, hepatitis B and influenza viruses. Its Panflu vaccine is available in China against the H5N1 influenza virus. Its pipeline consists of vaccine candidates in the pre-clinical and clinical development phases in China, including human vaccines for the EV71, Japanese encephalitis and rabies in pre-clinical development, a vaccine for the severe acute respiratory syndrome (SARS) virus that has completed a Phase I clinical trial and a split viron vaccine for the H5N1 influenza virus that has completed a Phase II clinical trial.